Meeting
2021 Genitourinary Cancers Symposium
Phase I study of AMG 509, a STEAP1 x CD3 T-cell recruiting XmAb 2+1 immune therapy, in patients with metastatic castration-resistant prostate cancer (mCRPC).
Authors
William Kevin Kelly
Thomas Jefferson University, Philadelphia, PA
William Kevin Kelly , David William Pook , Leonard Joseph Appleman , David Michael Waterhouse , Lisa Horvath , William Jeffery Edenfield , Nobuaki Matsubara , Daniel Costin Danila , Rahul Raj Aggarwal , Daniel Peter Petrylak , A. Oliver Sartor , Christopher Joseph Sumey , Nabil Adra , Andrew J. Armstrong , Fu-Chih Cheng , Julia Stieglmaier , Hosein Kouros-Mehr , Tanya B. Dorff
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session: Advanced Prostate Cancer
Track
Prostate Cancer - Advanced
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT04221542
Citation
J Clin Oncol 39, 2021 (suppl 6; abstr TPS183)
DOI
10.1200/JCO.2021.39.6_suppl.TPS183
Abstract #
TPS183
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Phase I study of AMG 509, a STEAP1 x CD3 T cell-recruiting XmAb 2+1 immune therapy, in patients with metastatic castration-resistant prostate cancer (mCRPC).
First Author: W. Kevin Kelly
Poster
2022 ASCO Annual Meeting
A phase 1 study of AMG 509 in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
First Author: Daniel Costin Danila
Poster
2020 Genitourinary Cancers Symposium
A phase I study to evaluate PSCA-targeting chimeric antigen receptor (CAR)-T cells for patients with PSCA+ metastatic castration-resistant prostate cancer (mCRPC).
First Author: Tanya B. Dorff
First Author: Mark T. Fleming